The Whole New World of SGLT-2 Inhibitors: Looking into the Cardio-Kidney-Metabolic Space
ACPE Number:0204-0000-24-406-H01-P Content Release Date: February 13, 2025 Expiration Date: February 13, 2026 Activity Type: Application-based CE Credits: 1.5 contact hours (0.15 CEUs) Activity Fee: Free
Activity Overview
This educational activity will provide an overview of CKM syndrome and evidence supporting early screening and treatment. The latest data from all landmark clinical trials, systematic reviews, and meta-analyses demonstrating the benefit of SGLT2 inhibitors on cardiorenal outcomes and clinical trials currently underway to identify potential emerging areas for SGLT2 inhibitor benefit will be presented. A review of the latest clinical practice guidelines for the use of SGLT2 inhibitors in heart failure, kidney disease, and diabetes will be shared. The activity will conclude with an exploration of interprofessional care models that address barriers and incorporate pharmacists into the initiation, titration, and monitoring of SGLT2 inhibitor therapy for patients who could benefit from treatment.
*Please note, this activity was presented live on December 9, 2024 as part of the ASHP 2024 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, community pharmacies, and ambulatory clinics who care for or are interested in the care of patients who have type 2 diabetes, heart failure, and/or chronic kidney disease.
After participating in this CPE activity, learners should be able to:
Identify people who have T2D, HF, and/or CKD who would benefit from early initiation of SGLT2 inhibitor therapy.
Formulate an evidence-based treatment plan to reduce cardiorenal risk in people with cardio-renal-metabolic comorbidities based on current clinical practice guidelines and person-specific factors.
Apply best practices from interprofessional care models that support the implementation of cardio-renal-metabolic therapies in different practice settings.
Dr. Leo F. Buckley is a clinical pharmacy specialist in the Department of Pharmacy at Brigham and Women's Hospital in Boston, Massachusetts. He graduated from Northeastern University's School of Pharmacy and completed residencies in Pharmacy Practice and Cardiovascular Pharmacotherapy at Brigham and Women's Hospital. After a research fellowship at Virginia Commonwealth University, he returned to Brigham and Women's where he leads a cardiovascular pharmacology research program and practices as a clinical pharmacist. His clinical and research interests include cardio-renal inflammation and metabolism.
Susan Cornell, PharmD, CDCES, FAPhA, FADCES Director of Experiential Education, Professor in Pharmacy Practice Midwestern University College of Pharmacy Downers Grove, IL Diabetes Care & Education Specialist Bolingbrook Christian Health Center Bolingbrook, Illinois
Dr. Susan Cornell is the director of experiential education and professor in the department of pharmacy practice at Midwestern University College of Pharmacy in Downers Grove, Illinois. Dr. Cornell is also a clinical pharmacist and certified diabetes care and education specialist with the Bolingbrook Christian Health Center, where she trains, educates, and supervises students from the colleges of medicine, pharmacy, and health sciences, as they provide medication therapy management and diabetes care and education for underserved populations.
Dr. Cornell served as President of the Illinois Pharmacists Association in 2011. She has received numerous awards and recognitions, including the 2024 APhA-ASP Outstanding Chapter Advisor Award, 2022 ADCES Allene Von Son Distinguished Serves Award, the 2021, 2019 and 2011 MWU Outstanding Faculty Advisor, 2017 ADCES Outstanding Illinois Diabetes Educator of the Year, and the 2014 Bowl of Hygeia, to list a few. She is an active member of the American Diabetes Association. She is also actively involved with the Association of Diabetes Care and Education Specialists, where she previously served on their board of directors and continues to assist on various committees.
Dr. Cornell has been invited to give numerous presentations to various healthcare professionals and community groups worldwide. She has served as editor, as well as, published and contributed to many peer-reviewed, professional written and online publications. Dr. Cornell is the associate editor of the ADCES Art and Science of Diabetes Care and Education Desk Reference- 3rd thru 6th edition.
Jeffery S. Vender, MD, MCCM, MBA is the Emeritus, Harris Family Foundation Chairman of the Department of Anesthesiology at NorthShore University Health System in Evanston, Illinois and a Clinical Professor at the University of Chicago Pritzker School Of Medicine in Chicago, Illinois. He is a past member of the NorthShore University Health System Faculty Practice Associates Board of Directors, Past Chair of the Medical Executive Committee for the Professional Staff at NorthShore and previously served on Northshore’s Board of Directors. Dr. Vender served as Chair of Anesthesia from 1990-2015 and received an appointment of adjunct Professor of Biomedical Engineering at Northwestern University. He served as the Director of the Critical Care Services at Evanston Hospital from 1987-2000 and the Interim Chairman at Northwestern University Department of Anesthesiology from July 1999 until October 2000. Dr. Vender has participated and Chaired numerous state and national committees of various medical organizations, edited several medical texts, has published over 135 articles and book chapters and has been an invited lecturer at over 250 national and international meetings on topics of anesthesiology, critical care, organizational change, and leadership. In addition, Dr. Vender serves as an editor and/or reviewer for many medical journals.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Susan Cornell: Novo Nordisk, Inc. – Advisory Board
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.
Provided by ASHP
Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.
